Bioxytran Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Bioxytran Inc (BIXT) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Bioxytran Inc vs Its Competitors
- Scale: Bioxytran Inc ranks #441 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Bioxytran Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Bioxytran Inc | - | - | - | No |
| Competitors combined (38) | ||||
| Similar-Size Competitors (9) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
BIXT Stock Performance relative to its Competitors
BIXT Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 2 | Nurix Therapeutics Inc | 282.9% | Outperformed |
| 3 | Enliven Therapeutics Inc | 282.9% | Outperformed |
| 4 | Oramed Pharmaceuticals Inc | 282.9% | Outperformed |
| 5 | Whitehawk Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Bioxytran Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Bioxytran Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Bioxytran Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Bioxytran Inc | 2.72 | - |
| Eli Lilly And Company | 1,060,477.83 | 79,665.80 |
| Madrigal Pharmaceuticals Inc | 14,771.11 | 1,283.94 |
| Nuvalent Inc | 9,751.98 | 4.23 |
| Rhythm Pharmaceuticals Inc | 6,639.77 | 239.92 |
| Terns Pharmaceuticals Inc | 4,933.17 | - |
| SUBTOTAL | 1,119,928.11 | 84,129.39 |
Sign in to see all competitors of Bioxytran Inc .
Sources: Bioxytran Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Bioxytran Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Bioxytran Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Rhythm Pharmaceuticals Inc | Single Reportable 100.00 % |
| Acadia Pharmaceuticals Inc | Reportable Segment Aggregation Before Other Operating Segment 100.00 % |
| Supernus Pharmaceuticals inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Bioxytran Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Bioxytran Inc | 3 | - | -1,746,899 |
| Eli Lilly And Company | 1,060,478 | 1,593,316 | 534,224 |
| Madrigal Pharmaceuticals Inc | 14,771 | 1,403,213 | -355,295 |
| Nuvalent Inc | 9,752 | 18,566 | -1,974,009 |
| Rhythm Pharmaceuticals Inc | 6,640 | 579,512 | -507,783 |
| Terns Pharmaceuticals Inc | 4,933 | - | -1,630,627 |
| PEERS TOTAL | 1,119,925 | 1,511,895 | 426,727 |
Bioxytran Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 61.21 % |
| Xoma Royalty Corporation | CH 54.36 % |
| Adc Therapeutics Sa | United States 96.08 % |
| Ree Automotive Ltd | France 8.26 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Bioxytran Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Bioxytran Inc's industry classification, broader than the peer set above. Market cap in millions of $.Bioxytran Inc ranks #441 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 824, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,058,704 | 19.37 % |
| 2 | Johnson and Johnson | 652,898 | 11.95 % |
| 3 | Beone Medicines Ltd | 549,864 | 10.06 % |
| 4 | Abbvie Inc | 466,251 | 8.53 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 441 | Bioxytran Inc | 3 | 0.00 % |
Market cap and industry share for the rest of Bioxytran Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-29.
Bioxytran Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 436 | Mustang Bio inc | 3 | -68.28 % |
| 437 | Cadrenal Therapeutics Inc | 3 | -92.05 % |
| 438 | Revelation Biosciences Inc | 3 | -85.31 % |
| 439 | Moleculin Biotech Inc | 3 | -95.43 % |
| 440 | Cv Sciences Inc | 1,234 | 12.3% |
| 441 | Bioxytran Inc | 3 | - |
| 442 | Immuron Limited | 1,234 | 12.3% |
| 443 | International Stem Cell Corporation | 1,234 | 12.3% |
| 444 | Azitra Inc | 1,234 | 12.3% |
| 445 | Addex Therapeutics Ltd | 1,234 | 12.3% |
| 446 | Alaunos Therapeutics Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Bioxytran Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-29. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Bioxytran Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (342 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | -0.9x | 4.5x | -5.4x |
| Return on Equity | 94.22 % | industry aggregate | 76.97 % |
| Return on Invested Capital | 49.77 % | -2.95 % (avg) | 52.72 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Bioxytran Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2017 | 2018 | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | -22.48 % | - | - | - | - | - | - | - |
| Operating Margin | -162.55 % | - | - | - | - | - | - | - |
| Return on Invested Capital | 114.16 % | -35.45 % | 99.13 % | 112.95 % | 27.59 % | 57.45 % | 78.54 % | 34.00 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Bioxytran Inc's BCG Growth-Share Matrix
Relative market share (vs Bioxytran Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Bioxytran Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Bioxytran Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 824 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Bioxytran Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Bioxytran Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Bioxytran Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Bioxytran Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Bioxytran Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 77.0 points above the industry aggregate.
Weaknesses
- Low relative market share vs the industry leader (0.00x).
Opportunities
- A meaningful share of tracked competitors (42.90 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Bioxytran Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Bioxytran Inc | 0.07 | 0.07 | - |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Madrigal Pharmaceuticals Inc | 0.72 | 3.52 | 0.60 |
| Nuvalent Inc | 1.98 | 13.90 | - |
| Rhythm Pharmaceuticals Inc | 1.14 | 4.16 | 0.84 |
| Terns Pharmaceuticals Inc | 17.26 | 35.60 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Bioxytran Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Bioxytran Inc | Q2 2026 | - | - |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Madrigal Pharmaceuticals Inc | Q2 2026 | +71.2 % | - |
| Nuvalent Inc | Q1 2026 | - | - |
| Rhythm Pharmaceuticals Inc | Q2 2026 | +46.9 % | - |
| Terns Pharmaceuticals Inc | Q4 2025 | - | - |
| PEERS TOTAL | +46.2 % | +29.3 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Bioxytran Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Bioxytran Inc | Q2 2026 | - | -38.1 % |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Madrigal Pharmaceuticals Inc | Q2 2026 | - | - |
| Nuvalent Inc | Q1 2026 | - | - |
| Rhythm Pharmaceuticals Inc | Q2 2026 | +61.1 % | - |
| Terns Pharmaceuticals Inc | Q4 2025 | - | - |
Bioxytran Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Bioxytran Inc | - | - | - |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Madrigal Pharmaceuticals Inc | - | - | - |
| Nuvalent Inc | - | - | - |
| Rhythm Pharmaceuticals Inc | - | - | - |
| Terns Pharmaceuticals Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Bioxytran Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Bioxytran Inc | - | - |
| Eli Lilly And Company | 39.83 | 13.31 |
| Madrigal Pharmaceuticals Inc | - | 11.50 |
| Nuvalent Inc | - | 2,303.80 |
| Rhythm Pharmaceuticals Inc | - | 27.68 |
| Terns Pharmaceuticals Inc | - | - |
| PEERS AVERAGE | 47.17 | 13.31 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.